Biotech Company Strengthens Board Experience VANCOUVER, British Columbia, Feb. 03, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the appointment of Dr. Victoria Hale to the company’s Board of Directors. Dr.


Previous articleSmall Pharma Reports Fiscal Third Quarter 2021 Highlights
Next articleSilo Pharma Extends Exclusive Option Agreement for Homing Peptides